SCHEMBL6208348

SCHEMBL6208348

CCc1ccc(Nc2c(-c3nnc(N4CCCN(Cc5ccccc5)CC4)o3)ccc(F)c2F)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 1/20 0.37
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
BACE1 P56817 2/20 0.36
MAPT P10636 4/20 0.36
ACP1 P24666 2/20 0.36
CHKA P35790 2/20 0.36
CASP1 P29466 1/20 0.35
CASP5 P51878 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
KCNH2 Q12809 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6206805 0.88 BCHE (0.39) BCHEACHEBACE1MAPTMEN1
SCHEMBL6404616 0.88 BCHE (0.37) BCHEACHEBACE1MAPTTSHR
SCHEMBL6207211 0.88 BCHE (0.37) BCHEACHEBACE1KDM4E
SCHEMBL6403567 0.87 BCHE (0.43) BCHEACHEBACE1MAPTALDH1A1
SCHEMBL6230497 0.87 KCNH2 (0.38) BCHEACHEBACE1CHKACASP1
SCHEMBL6206922 0.85 BCHE (0.37) BCHEACHEBACE1CASP1ALDH1A1
SCHEMBL6205424 0.84 ACHE (0.56) BCHEACHEBACE1MAPT
SCHEMBL6208052 0.81 HRH3 (0.34) BCHEACHEBACE1CYP3A4KCNH2
SCHEMBL6207402 0.76 AVPR1A (0.33) BCHEACHEBACE1
SCHEMBL6207041 0.75 KDM4E (0.47) MAPTALDH1A1CYP3A4KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO claimed
US-20050239751-A1 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses RIGEL PHARMACEUTICALS, INC. (US) 2005-10-27 US disclosed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 EEF2K 137/4885BCHE 3693/4885ACHE 2974/4885
US-20050239751-A1 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses HAVCR2, HCCS, AADAC EEF2K 1323/4885BCHE 1184/4885ACHE 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.